PBYI – Puma Biotechnology, Inc.
Puma Biotechnology IncPBYI
$3.01Name : Puma Biotechnology Inc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $149,410,688.00
EPSttm : 0.78
Puma Biotechnology Inc
$3.01
0.99%$0.03Float Short %
7.54
Margin Of Safety %
45
Put/Call OI Ratio
0.03
EPS Next Q Diff
0.11
EPS Last/This Y
-0.24
EPS This/Next Y
0.03
Price
3.01
Target Price
4.33
Analyst Recom
3
Performance Q
9.06
Relative Volume
0.81
Beta
1.26
Ticker: PBYI
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | PBYI | 2.93 | 0.04 | 0.00 | 2131 |
| 2025-04-15 | PBYI | 2.96 | 0.04 | 6.67 | 2131 |
| 2025-04-16 | PBYI | 2.91 | 0.05 | 999.99 | 2156 |
| 2025-04-17 | PBYI | 2.85 | 0.06 | 0.00 | 2166 |
| 2025-04-18 | PBYI | 2.86 | 0.06 | 0.00 | 2166 |
| 2025-04-21 | PBYI | 2.86 | 0.05 | 0.00 | 1998 |
| 2025-04-22 | PBYI | 3.01 | 0.05 | 0.00 | 2011 |
| 2025-04-23 | PBYI | 3.03 | 0.04 | 0.00 | 2144 |
| 2025-04-24 | PBYI | 3 | 0.04 | 0.00 | 2157 |
| 2025-04-25 | PBYI | 3 | 0.042145593869732 | 0 | 2176 |
| 2025-04-28 | PBYI | 2.98 | 0.041686404547608 | 0 | 2199 |
| 2025-04-29 | PBYI | 3.04 | 0.04 | 0.00 | 2199 |
| 2025-04-30 | PBYI | 3.17 | 0.04 | 0.06 | 2217 |
| 2025-05-01 | PBYI | 3.08 | 0.04 | 0.00 | 2260 |
| 2025-05-02 | PBYI | 3.2 | 0.04 | 0.00 | 2260 |
| 2025-05-05 | PBYI | 3.08 | 0.04 | 0.00 | 2275 |
| 2025-05-06 | PBYI | 3 | 0.04 | 0.00 | 2284 |
| 2025-05-07 | PBYI | 2.99 | 0.04 | 0.08 | 2283 |
| 2025-05-08 | PBYI | 3.05 | 0.04 | 0.00 | 2279 |
| 2025-05-09 | PBYI | 2.91 | 0.04 | 0.00 | 2466 |
| 2025-05-12 | PBYI | 3.05 | 0.03 | 0.00 | 2620 |
| 2025-05-13 | PBYI | 3.01 | 0.03 | 0.20 | 2724 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | PBYI | 2.93 | 150.0 | - | 0.54 |
| 2025-04-15 | PBYI | 2.96 | 150.0 | - | 0.54 |
| 2025-04-16 | PBYI | 2.88 | 150.0 | - | 0.54 |
| 2025-04-17 | PBYI | 2.86 | 150.0 | - | 0.54 |
| 2025-04-18 | PBYI | 2.86 | 150.0 | - | 0.54 |
| 2025-04-21 | PBYI | 2.86 | 150.0 | - | 0.54 |
| 2025-04-22 | PBYI | 3.01 | 150.0 | - | 0.54 |
| 2025-04-23 | PBYI | 3.03 | 150.0 | - | 0.54 |
| 2025-04-24 | PBYI | 3.00 | 150.0 | - | 0.54 |
| 2025-04-25 | PBYI | 3.00 | 150.0 | - | 0.54 |
| 2025-04-28 | PBYI | 2.98 | 150.0 | - | 0.54 |
| 2025-04-29 | PBYI | 3.04 | 150.0 | - | 0.54 |
| 2025-04-30 | PBYI | 3.18 | 150.0 | - | 0.54 |
| 2025-05-01 | PBYI | 3.08 | 150.0 | - | 0.54 |
| 2025-05-02 | PBYI | 3.21 | 150.0 | - | 0.54 |
| 2025-05-05 | PBYI | 3.07 | 150.0 | - | 0.54 |
| 2025-05-06 | PBYI | 2.98 | 150.0 | - | 0.54 |
| 2025-05-07 | PBYI | 2.99 | 150.0 | - | 0.54 |
| 2025-05-08 | PBYI | 3.06 | 150.0 | - | 0.54 |
| 2025-05-09 | PBYI | 2.92 | 150.0 | - | 0.54 |
| 2025-05-12 | PBYI | 3.04 | 150.0 | - | 0.54 |
| 2025-05-13 | PBYI | 3.01 | 150.0 | - | 0.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | PBYI | -0.57 | -11.02 | 7.42 |
| 2025-04-15 | PBYI | -0.57 | -11.02 | 7.42 |
| 2025-04-16 | PBYI | -0.57 | -11.02 | 7.42 |
| 2025-04-17 | PBYI | -0.57 | -11.02 | 7.42 |
| 2025-04-18 | PBYI | -0.57 | -11.02 | 7.42 |
| 2025-04-21 | PBYI | -0.57 | -11.07 | 7.42 |
| 2025-04-22 | PBYI | -0.57 | -11.07 | 7.42 |
| 2025-04-23 | PBYI | -0.57 | -11.07 | 7.42 |
| 2025-04-24 | PBYI | -0.57 | -11.07 | 7.42 |
| 2025-04-25 | PBYI | -0.57 | -11.07 | 7.42 |
| 2025-04-28 | PBYI | -0.57 | -14.20 | 7.38 |
| 2025-04-29 | PBYI | -0.57 | -14.20 | 7.38 |
| 2025-04-30 | PBYI | -0.57 | -14.20 | 7.38 |
| 2025-05-01 | PBYI | -0.57 | -14.20 | 7.38 |
| 2025-05-02 | PBYI | -0.57 | -14.20 | 7.38 |
| 2025-05-05 | PBYI | -0.57 | -14.44 | 7.38 |
| 2025-05-06 | PBYI | -0.57 | -14.44 | 7.38 |
| 2025-05-07 | PBYI | -0.57 | -14.44 | 7.38 |
| 2025-05-08 | PBYI | -0.57 | -14.44 | 7.38 |
| 2025-05-09 | PBYI | -0.57 | -14.44 | 7.38 |
| 2025-05-12 | PBYI | -0.57 | -10.87 | 7.54 |
| 2025-05-13 | PBYI | -0.57 | -10.87 | 7.54 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.06
Avg. EPS Est. Current Quarter
0.03
Avg. EPS Est. Next Quarter
0.17
Insider Transactions
-0.57
Institutional Transactions
-10.87
Beta
1.26
Average Sales Estimate Current Quarter
44
Average Sales Estimate Next Quarter
52
Fair Value
4.37
Quality Score
96
Growth Score
54
Sentiment Score
34
Actual DrawDown %
78.7
Max Drawdown 5-Year %
-88
Target Price
4.33
P/E
3.91
Forward P/E
9.31
PEG
P/S
0.64
P/B
1.54
P/Free Cash Flow
4.79
EPS
0.77
Average EPS Est. Cur. Y
0.54
EPS Next Y. (Est.)
0.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
16.36
Relative Volume
0.81
Return on Equity vs Sector %
15.5
Return on Equity vs Industry %
32.5
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.09
EBIT Estimation
Puma Biotechnology IncSector: Healthcare
Industry: Biotechnology
Employees: 172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today
news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance
stock history PBYI – Puma Biotechnology, Inc. invest stock market
stock prices PBYI premarket after hours
ticker PBYI fair value insiders trading